Abstract
Significant progress in the development of potent and selective histamine H1-receptor agonists has been achieved since 1990. Optimisation of the class of 2-phenylhistamines has furnished 2-[3- (trifluoromethyl)phenyl]histamine and its Nα-methyl derivative. The discovery of histaprodifen (2-[2-(3,3- diphenylpropyl)-1H-imidazol-4-yl]ethanamine) and the novel lead compound suprahistaprodifen (Nα-2-[(1Himidazol- 4-yl)ethyl]histaprodifen) represents additional milestones in the H1-receptor agonist field.
Keywords: histaprodifen, suprahistaprodifen, h1-receptor agonist, partial agonist, guinea-pig ileum, guinea-pig aorta, guineapig trachea, rat aorta
Mini-Reviews in Medicinal Chemistry
Title: Structure-Activity Relationships of Histamine H1-Receptor Agonists
Volume: 4 Issue: 9
Author(s): Heinz H. Pertz, Sigurd Elz and Walter Schunack
Affiliation:
Keywords: histaprodifen, suprahistaprodifen, h1-receptor agonist, partial agonist, guinea-pig ileum, guinea-pig aorta, guineapig trachea, rat aorta
Abstract: Significant progress in the development of potent and selective histamine H1-receptor agonists has been achieved since 1990. Optimisation of the class of 2-phenylhistamines has furnished 2-[3- (trifluoromethyl)phenyl]histamine and its Nα-methyl derivative. The discovery of histaprodifen (2-[2-(3,3- diphenylpropyl)-1H-imidazol-4-yl]ethanamine) and the novel lead compound suprahistaprodifen (Nα-2-[(1Himidazol- 4-yl)ethyl]histaprodifen) represents additional milestones in the H1-receptor agonist field.
Export Options
About this article
Cite this article as:
Pertz H. Heinz, Elz Sigurd and Schunack Walter, Structure-Activity Relationships of Histamine H1-Receptor Agonists, Mini-Reviews in Medicinal Chemistry 2004; 4 (9) . https://dx.doi.org/10.2174/1389557043403198
DOI https://dx.doi.org/10.2174/1389557043403198 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Properties and Potency of Small Molecule Agents for Treatment of Mycobacterium Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Bacterial Siderophores and Their Potential Applications: A Review
Current Molecular Pharmacology Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Respiratory Medicine Reviews Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Mass Spectrometry, Proteomics, Data Mining Strategies and Their Applications in Infectious Disease Research.
Anti-Infective Agents in Medicinal Chemistry Perspectives in Genomics The Future of Fungi in ‘omics’ era
Current Genomics Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology Role of the Bacterial Type VI Secretion System in the Modulation of Mammalian Host Cell Immunity
Current Medicinal Chemistry Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis
Current Drug Targets Extracellular Enzymes Production and Biofilm Formation in Rhodotorula Species
Current Enzyme Inhibition Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry